Apr 06,2020

Findings on remote patient monitoring for better asthma control: Research posters from AAAAI 2020

The American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting couldn’t take place this year due to the novel coronavirus (COVID-19) pandemic. However, there’s still a wealth of newly published research posters from the conference available online. Propeller contributed to six posters with research partners at Northshore University Health System, Children’s Hospital Colorado and Northwestern University Feinberg School of Medicine.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 08,2023

DIGITAL THERAPEUTICS STARTUP RESPIREE™ GAINS US FDA CLEARANCE FOR ITS RS001 CARDIO-RESPIRATORY WEARABLE

Digital therapeutics startup, Respireetm, has received clearance from the US Food and Drug Administration (FDA) for its RS001 cardio-respiratory wearable, according to a press release. The wearable device measures respiration directly and can be used on patients suffering from cardio-pulmonary diseases such as chronic obstructive pulmonary disease (COPD) and congestive heart failure. The collected data is then transmitted to healthcare providers, who can use it to monitor patients remotely and provide real-time interventions. The FDA clearance is a significant milestone for Respireetm, allowing the company to market and distribute the RS001 wearable in the US. This approval highlights the growing trend towards remote patient monitoring and digital health solutions.

REGULATORY FDA

#connected device

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 26,2023

Luscii + EXI: The New Partnership that Brings Health-Enhancing Exercise to Virtual Hospital Wards

Digital health platform Luscii, market leader in the growing space of virtual hospital wards, has announced a new partnership with digital therapeutic EXI that will allow it to integrate physical activity into its care pathways for the first time. With over 15 years' experience across 11 markets, and as a partner of NHS England, Luscii provides over 100 different care pathways. These enable patients with a broad range of health conditions - from pregnancy and menopause to cardiac rehab, diabetes and several types of cancer- to be monitored remotely. EXI - whose Software as a Medical Device (SaMD) platform is proven for 23 long-term health conditions and co-morbidities - will be the partner to integrate across multiple care pathways. EXI draws on the latest clinical evidence for behavioural science and exercise to prescribe personalised physical activity for those with long-term health conditions and co-morbidities. Adherence, activity and health data is also sent directly to the clinician, in real time, through a secure practitioner portal. Initially launching into Luscii's cardiology and COPD pathways in the UK and Ireland, it is envisioned that EXI will, in time, be integrated into every pathway across all markets

COLLABORATION PARTNERSHIP

#connected device

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 21,2023

Welby Establishes “Oncology PHR Consortium” and Starts Joint Project for Clinical Implementation of PHR with National Cancer Center Hospital

Welby Co., Ltd. aims to realize patient-centered cancer treatment and improve treatment outcomes through PHR (Personal Health Record). In addition, as an initiative of the “Oncology PHR Consortium”, Welby has started a joint project with the National Cancer Center and other cancer treatment hospitals. The 4th Basic Plan for the Promotion of Cancer Control, which will start this fiscal year, calls for the promotion of digitalization as a foundation to support cancer prevention, cancer treatment, and coexistence with cancer.

COLLABORATION PARTNERSHIP

#institution

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 30,2023

Kaiku Health Digital Patient Monitoring enhances the early detection of evolving peripheral sensory neuropathy and reduces phone call burden

Oulu University Hospital, Vaasa Central Hospital and Elekta (Kaiku Health) have published the first scientific results from a study investigating the use of digital patient monitoring for colorectal cancer (CRC) patients receiving oxaliplatin-based chemotherapy. The study was designed to investigate whether digital patient monitoring could enhance and personalize symptom management as well as improve patient follow-up and empowerment while simplifying care teams’ workflow. In this multicenter trial, Kaiku Health digital patient monitoring platform was provided for CRC patients with advanced disease receiving oxaliplatin-based chemotherapy in the first- or second-line setting or as an adjuvant treatment. Patients received weekly reminders to report on their symptoms through the platform and the care team was notified in the presence of more severe symptoms or unfavorable development. The results generated in the prospective study were compared to a retrospective cohort curated from the patient records at the same institutes. A specific adverse effect of interest in the study was peripheral sensory neuropathy. In the study, earlier detection of peripheral sensory neuropathy (p = 1e?5), did not translate to earlier dose reduction, delays, or unplanned therapy termination compared to the retrospective cohort. In addition, the feasibility of the ePRO follow-up was found to be good with 98% of the patients reporting that the use of the platform was very easy or easy to use.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 23,2023

Huma receives world’s first and only multi-condition EU MDR Class IIb regulatory approval for its configurable SaMD disease management platform

Huma Therapeutics today announced that it has become the only company in the world to receive EU MDR 2017/745 Class IIb certification for a disease agnostic Software as a Medical Device (SaMD). Achieving Class IIb certification means that the SaMD platform is permitted to monitor patients of all ages with any condition - including infants and in pregnancy - and can connect with a range of external devices, such as heart rate, blood sugar monitors or smart inhalers. In addition to enabling disease self-management by patients, it can also support clinicians to manage serious and critical conditions such as heart failure, COPD exacerbations, surgical recovery, cancer, immunodeficiency, asthma attacks and more.

REGULATORY CE MARK

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 16,2023

Leading Oncology Patient-Reported Outcomes Technology Company Launches Commercialization of Computerized Cancer Symptom Management Pathways

Carevive Systems, Inc., a leading innovator in cancer care management software with a deep real-world evidence patient dataset, announced today that it will launch the commercialization of its computerized cancer symptom management pathways. These pathways were developed through the generous support of a multi-million-dollar Phase I/II Small Business Innovations Research contract funded by the National Cancer Institute. This product took over five years to develop, test, and pilot with input from an international panel of cancer symptom experts. Symptom management is a focus of the Cancer Moonshot Initiative. Carevive is the only company that applied for and received a Fast-Track Phase I/II contract award from the NCI under this research topic. With Carevive PROmpt®, patients are systematically monitored remotely every week, and the care team is notified electronically when patients report symptoms that may require clinical intervention. With the launch of Carevive STAIRS™, when nurses or MAs receive a notification, they can now use structured, decision-tree-based questions when following up with patients to triage and assess symptoms, and the system will offer recommended evidence-based management strategies for consideration.

PRODUCT

#rpm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 13,2023

Glytec Unveils the Next Evolution of GlucoMetrics®, Giving Hospital Leaders New Insights and Analytics to Improve Glycemic Management and Readiness for New CMS Measures

Glytec today announced the next evolution of GlucoMetrics® to provide new analytics, dashboards, and data visualizations that give hospitals and health systems new insight into glycemic outcomes. The enhanced visibility comes as hospitals prepare for new measures from the Centers for Medicare and Medicaid Services (CMS) on severe hypoglycemia and hyperglycemia that encourage facilities to report metrics starting in early 2024. GlucoMetrics is powered by data from Glytec’s eGlycemic Management System® (eGMS). Centered on Glucommander,® eGMS is an EHR-integrated, HITRUST certified, cloud-based software system that supports personalized insulin dosing decision support at the point of care. With significant enhancements to GlucoMetrics, glycemic management committees and hospital leaders now have self-serve access to key performance indicators, trends, and benchmarks related to glycemia treatment across their entire health system.

PRODUCT

#rpm

View Analyst & Ambassador Comments
Go to original news
Apr 11,2023

Glooko Announces Partnership with Insulin Dosing Algorithm Company Hedia

Glooko, Inc., announced today a new Global partnership with Hedia, integrating its technology into Glooko's diabetes management platforms for healthcare providers and people with diabetes. With the Glooko platforms, patients currently have the ability to share their diabetes data with their healthcare providers (HCPs), including blood glucose readings, insulin doses, food and carbs, exercise activity, blood pressure and weight. With the integration of Hedia Diabetes Assistant, people with diabetes will be able to receive bolus insulin dosing advice, which will provide personalized care and reduce the burden of manually calculating required insulin doses. In addition, when used in conjunction with connected insulin pens, the integrated solution facilitates a high level of visibility for HCPs who are managing patients on multiple daily injection (MDI) therapy. The initial European launch of the integration is expected in the fourth quarter of 2023 and first quarter of 2024.

COLLABORATION PARTNERSHIP

#connected device

#dtx

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 27,2023

Philips unveils new Virtual Care Management portfolio

Philips announced today that it debuted its Philips Virtual Care Management portfolio of flexible solutions and services. The Amsterdam-based medtech giant aims to help health systems, providers, payers and employers connect with patients from virtually anywhere. It designed the portfolio to reduce pressure on hospital staff by decreasing emergency department visits and reducing care costs by better managing chronic care. Philips Virtual Care Management’s condition-specific protocols now include diabetes, hypertension, chronic kidney disease, chronic obstructive pulmonary disease (COPD) and heart disease. These protocols combine with connected devices and engagement tools on a secure, interoperable cloud-based platform. Licensed clinical professionals offer monitoring and personalized coaching, while Philips brings expert-led professional services. Philips said its virtual care program “goes beyond traditional remote patient management.” It features scalable solutions and services to foster patient engagement and empower healthier behaviors.

PRODUCT

#virtual care

#rpm

View Analyst & Ambassador Comments
Go to original news
Subscribe to RPM